bluuebunny/crossref_metadata_2025_split huggingface dataset:
The role of Quaternary glaciations in shaping biogeographic patterns in a recently evolved clade of South American epiphytic orchids
Authors: Pessoa Edlley M , Cordeiro Joel M P , Felix Leonardo P , Lemes Priscila , Viruel Juan , Alves Marccus , Chase Mark W , Van Den Berg Cássio 
Published: May 2021

AbstractTo contribute to what is known about involvement of vegetation dynamics in Neotropical speciation, we used the Epidendrum latilabre complex, a taxonomically well-defined species group, to investigate past connections between Amazonian (AM) and Atlantic (AF) forests and address the following topics: (1) divergence times between sister species currently distributed in AM and AF; (2) distribution patterns of ancestral species of the E. latilabre complex and (3) potential routes connecting ancestral ranges between AM and AF. We developed a robust phylogenetic estimate for species of the E. latilabre complex by sequencing two nuclear and six plastid loci. Then, we combined divergence time estimation, ancestral range reconstruction and ecological niche modelling. Our biogeographic reconstruction exhibits a complex pattern of connections among tropical forests east of the Andes in South America. The AM and AF species of the E. latilabre complex are intermixed in the results, and climatic shifts during the Pleistocene (Chibanian) are suggested here as a major force promoting speciation. Sister species tend to be ecologically distinct in their climate niche spaces, and vicariance and peripheral isolation are reconstructed as the main drivers of speciation. There is evidence to suggest that the south-east/north-west bridge and the northern/north-eastern coastal route have been occupied by the ancestors of the E. latilabre complex, and alternative routes across the South American dry diagonal were unlikely. Further studies on Neotropical epiphytic taxa are still necessary for understanding the dynamics of historical connections between AM and AF.
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
Authors: Chodick Gabriel , Tene Lilac , Rotem Ran S , Patalon Tal , Gazit Sivan , Ben-Tov Amir , Weil Clara , Goldshtein Inbal , Twig Gilad , Cohen Dani , Muhsen Khitam 
Published: May 2021

Abstract

Background
Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and mortality.

Methods
This historical cohort study included members of a large health provider in Israel that were vaccinated with at least 1 dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with real-time polymerase chain reaction (rt-PCR), between 7 and 27 days after second dose (protection-period), as compared to days 1–7 after the first dose, where no protection by the vaccine is assumed (reference-period).

Results
Data of 1 178 597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD = 18.1], 48.4% males) of whom 872 454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100 000 (95% confidence interval [CI]: 26.1–115.0 per 100 000) and 5.4 per 100 000 (95% CI: 3.5–8.4 per 100 000), respectively. The vaccine effectiveness in preventing infection was 90% (95% CI: 79%–95%) and 94% (95% CI: 88%–97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95% CI: 37%–87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95% CI: .36–1.88), 0.45 (95% CI: .23–.90), and 0.56 (95% CI: .36–.89) in the age groups 16–44, 45–64. and ≥75 years, respectively.

Conclusions
The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.
Why do disequilibria exist? An ontological study of Kirznerian economics
Authors: Ramoglou Stratos 
Published: May 2021

AbstractIn his influential critique of mainstream economics, Israel Kirzner rejected the notion of equilibrated economies in an attempt to develop a realistic account of the workings of entrepreneurial markets. Key to Kirznerian analysis are the arguments that (i) economies do not equilibrate because there always exist unexploited opportunities, and (ii) opportunities remain unexploited until ‘entrepreneurially alert’ individuals discover them. This paper draws from Tony Lawson’s philosophy of economics to explain that Kirznerian economics is no more realistic than mainstream. According to Lawson, it is the ontological commitment to closed systems thinking—not superficial theoretical features such as equilibrium—that makes mainstream economics unrealistic. I argue that Kirzner’s theoretical system similarly presupposes a closed system ontology. Whereas the mainstream worldview presumes the instant exploitation of opportunities, the Kirznerian worldview presumes their delayed yet unavoidable exploitation. The ontological critique of Kirznerian economics simultaneously facilitates the reorientation of entrepreneurship theory towards genuinely realistic modes of thought. This is feasible once we acknowledge the non-empirical ontology of ‘entrepreneurial opportunity’ and concomitant fallibility of the ‘entrepreneurial imagination’: opportunities remain unexploited because (inter alia) their existence is known only after their actualisation. The existence of economic disequilibria does not require non-actors who are blind to opportunities, and there is no mysterious force of ‘entrepreneurial alertness’ guaranteeing their eventual exploitation and inevitable movement towards economic equilibria.
Kardia Mobile and ISTEL HR applicability in clinical practice: a comparison of Kardia Mobile, ISTEL HR, and standard 12-lead electrocardiogram records in 98 consecutive patients of a tertiary cardiovascular care centre
Authors: Krzowski Bartosz , Skoczylas Kamila , Osak Gabriela , Żurawska Natalia , Peller Michał , Kołtowski Łukasz , Zych Aleksandra , Główczyńska Renata , Lodziński Piotr , Grabowski Marcin , Opolski Grzegorz , Balsam Paweł 
Published: May 2021

Abstract

Aims
Mobile, portable ECG-recorders allow the assessment of heart rhythm in out-of-hospital conditions and may prove useful for monitoring patients with cardiovascular diseases. However, the effectiveness of these portable devices has not been tested in everyday practice.

Methods and results
A group of 98 consecutive cardiology patients [62 males (63%), mean age 69 ± 12.9 years] were included in an academic care centre. For each patient, a standard 12-lead electrocardiogram (SE), as well as a Kardia Mobile 6L (KM) and Istel (IS) HR-2000 ECG were performed. Two groups of experienced physicians analysed obtained recordings. After analysing ECG tracings from SE, KM, and IS, quality was marked as good in 82%, 80%, and 72% of patients, respectively (P &lt; 0.001). There were no significant differences between devices in terms of detecting sinus rhythm [SE (60%, n = 59), KM (58%, n = 56), and IS (61%, n = 60); SE vs. KM P = 0.53; SE vs. IS P = 0.76) and atrial fibrillation [SE (22%, n = 22), KM (22%, n = 21), and IS (18%, n = 18); (SE vs. KM P = 0.65; SE vs. IS = 0.1)]. KM had a sensitivity of 88.1% and a specificity of 89.7% for diagnosing sinus rhythm. IS showed 91.5% and 84.6% sensitivity and specificity, respectively. The sensitivity of KM in detecting atrial fibrillation was higher than IS (86.4% vs. 77.3%), but their specificity was comparable (97.4% vs. 98.7%).

Conclusion
Novel, portable devices are useful in showing sinus rhythm and detecting atrial fibrillation in clinical practice. However, ECG measurements concerning conduction and repolarization should be clarified with a standard 12-lead electrocardiogram.
Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis
Authors: Stephen Ruth , Ngandu Tiia , Liu Yawu , Peltonen Markku , Antikainen Riitta , Kemppainen Nina , Laatikainen Tiina , Lötjönen Jyrki , Rinne Juha , Strandberg Timo , Tuomilehto Jaakko , Vanninen Ritva , Soininen Hilkka , Kivipelto Miia , Solomon Alina ,   FINGER Study Group
Published: May 2021

Abstract
The CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Risk Score is a validated tool estimating dementia risk. It was previously associated with imaging biomarkers. However, associations between dementia risk scores (including CAIDE) and dementia-related biomarkers have not been studied in the context of an intervention. This study investigated associations between change in CAIDE score and change in neuroimaging biomarkers (brain magnetic resonance imaging [MRI] and Pittsburgh Compound B-positron emission tomography [PiB-PET] measures) during the 2-year Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) (post-hoc analyses). FINGER targeted at-risk older adults, aged 60–77 years, from the general population. Participants were randomized to either multidomain intervention (diet, exercise, cognitive training, and vascular risk management) or control group (general health advice). Neuroimaging (MRI and PiB-PET) data from baseline and 2-year visits were used. A toal of 112 participants had repeated brain MRI measures (hippocampal, total gray matter, and white matter lesion volumes, and Alzheimer’s disease signature cortical thickness). Repeated PiB-PET scans were available for 39 participants. Reduction in CAIDE score (indicating lower dementia risk) during the intervention was associated with less decline in hippocampus volume in the intervention group, but not the control group (Randomization group × CAIDE change interaction β coefficient = −0.40, p = .02). Associations for other neuroimaging measures were not significant. The intervention may have benefits on hippocampal volume in individuals who succeed in improving their overall risk level as indicated by a reduction in CAIDE score. This exploratory finding requires further testing and validation in larger studies.
The Immunity Clock
Authors: Martínez de Toda Irene , Vida Carmen , Díaz-Del Cerro Estefanía , De la Fuente Mónica 
Published: May 2021

Abstract
The immune system has been for long considered a marker of health. The age-related decline in its function results in a greater incidence of infections, autoimmune diseases, and cancer. Nevertheless, it is still not known if immune function can be used to accurately estimate the rate of aging of an individual. A set of 14 immune function variables were measured in 214 healthy individuals ranging from 19 to 88 years old. All immune variables were selected as independent variables for the prediction of age by multiple linear regression. The Immunity Clock was constructed including the following 5 immune variables: natural killer activity, phagocytosis and chemotaxis of neutrophils, and chemotaxis and proliferative capacity of lymphocytes, reaching an adjusted R2 of 80.3% and a standard error of the estimate of 4.74 years. The Immunity Clock was validated in a different group of healthy individuals (N = 106) obtaining a Pearson’s correlation coefficient of .898 (p &lt; .001) between chronological age and the age estimated by the Immunity Clock, the ImmunolAge. Moreover, we demonstrate that women with anxiety (N = 10) show a higher ImmunolAge than their chronological age, whereas healthy centenarians (N = 8) show a lower one. In addition, the Immunity Clock provided here proves to be useful for monitoring the effectiveness of a nutritional intervention lasting 1 month, by detecting a diminished ImmunolAge in the same individuals. Further research will be needed to ascertain if the Immunity Clock is a passive marker of the aging process or it plays an active role in it.
Spillover Benefits and Achieving Sustainability of Age-Friendly Communities
Authors: Coyle Caitlin E , Gleason Shayna R , Mutchler Jan E 
Published: May 2021

Abstract
As the age-friendly movement grows in its second decade, urgent questions of initiative sustainability have taken hold in the academic literature and among advocates implementing age-friendly changes. The creation of authentically age-inclusive environments requires not just the continuation of the initiative, but that its principles become embedded in formal and informal organizational processes, across sectors and beyond familiar networks focused on older populations. This embedding ensures the initiative’s values take root permanently in a community’s institutional culture. This article argues that the sustainability of age-friendly initiatives is enhanced by “spillover” effects, in which a behavioral or policy change in one environment spurs change in another environment. Evidence for such spillover and an understanding of how and when it occurs is currently limited in the context of age-friendly environments. This article draws on the experiences of Age-Friendly Boston, which has been working toward age-friendly goals for more than 5 years. Based on Boston’s experience, we identify, describe, and exemplify 3 pathways to positive spillover across environments: (a) branding positively, (b) publicizing successes, and (c) embarking on new relationships, while strengthening existing ones, in pursuit of shared goals. We also draw conclusions about what positive spillover means for the sustainability of age-friendly environments.
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017: data collection, management and analysis
Authors: Bruyndonckx Robin , Adriaenssens Niels , Versporten Ann , Hens Niel , Monnet Dominique L , Molenberghs Geert , Goossens Herman , Weist Klaus , Coenen Samuel ,   the ESAC-Net study group, Strauss Reinhild , Vandael Eline , Sabtcheva Stefana , Payerl-Pal Marina , Kyriakidou Isavella , Vlček Jiří , Sönksen Ute Wolff , Linask Elviira , Sarvikivi Emmi , Cavalié Philippe , Feig Marcel , Kontopidou Flora , Benkő Ria , Aspelund Gudrun , Oza Ajay , Fortinguerra Filomena , Rutkovska Ieva , Kuklytė Jolanta , Bruch Marcel , Zarb Peter , Natsch Stephanie , Blix Hege Salvesen , Olczak-Pieńkowska Anna , Silva Ana , Iosif Ionel , Tesař Tomáš , Čižman Milan , Herreras Mayte Alonso , Bergfeldt Vendela , Hopkins Susan 
Published: May 2021

Abstract

Objectives
This article introduces a series of articles on antibiotic consumption in the community between 1997 and 2017, which provide an update of previous articles covering the periods 1997–2003 and 1997–2009.

Methods
In this article, differences in participating countries, the ATC/DDD classification system, and data collection, validation and analysis between the current and previous series are described.

Results
In the previous series, 33 European countries provided valid data for further analysis, while the current series focused on 30 countries belonging to the EU or the European Economic Area (EEA). For both series, data were collected in accordance with the WHO ATC classification system. While the previous series reported data in accordance with the ATC/DDD index 2011, the current series employed the ATC/DDD index 2019. Both series focused on consumption of antibacterials for systemic use (ATC J01) and collected data expressed in DDD per 1000 inhabitants per day and packages per 1000 inhabitants per day. When studying consumption expressed in packages per 1000 inhabitants per day, countries reporting total care data, i.e. community and hospital sector combined, were included in the previous series but excluded in the current series. While the previous series used non-linear mixed models to evaluate time trends in antibiotic consumption, the current series allowed for inclusion of change-points with a data-driven location. In addition, both series assessed the composition and quality of antibiotic consumption in the EU/EEA.

Conclusions
The updated analyses of two decades of ESAC-Net data provide the most comprehensive and detailed description of antibiotic consumption in the community in Europe.
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017
Authors: Bruyndonckx Robin , Adriaenssens Niels , Versporten Ann , Hens Niel , Monnet Dominique L , Molenberghs Geert , Goossens Herman , Weist Klaus , Coenen Samuel ,   the ESAC-Net study group, Strauss Reinhild , Vandael Eline , Sabtcheva Stefana , Andrašević Arjana Tambić , Kyriakidou Isavella , Vlček Jiří , Sönksen Ute Wolff , Linask Elviira , Sarvikivi Emmi , Hider-Mlynarz Karima , Richter Doreen , Kontopidou Flora , Matuz Mária , Aspelund Gudrun , Burns Karen , Fortinguerra Filomena , Dimina Elīna , Kuklytė Jolanta , Bruch Marcel , Zarb Peter , Natsch Stephanie , Blix Hege Salvesen , Olczak-Pieńkowska Anna , Silva Ana , Popescu Gabriel Adrian , Tesař Tomáš , Čižman Milan , Navas Antonio López , Bergfeldt Vendela , Hopkins Susan 
Published: May 2021

Abstract

Objectives
Data on antibiotic consumption in the community were collected from 30 EU/EEA countries over two decades. This article reviews temporal trends, seasonal variation, presence of change-points and changes in the composition of the main antibiotic groups.

Methods
For the period 1997–2017, data on consumption of antibiotics, i.e. antibacterials for systemic use (ATC group J01), in the community, aggregated at the level of the active substance, were collected using the WHO ATC/DDD methodology (ATC/DDD index 2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per 1000 inhabitants per day. Antibiotic consumption was analysed based on ATC-3 groups, and presented as trends, seasonal variation, presence of change-points and compositional changes.

Results
In 2017, antibiotic consumption in the community expressed in DDD per 1000 inhabitants per day varied by a factor 3.6 between countries with the highest (Greece) and the lowest (the Netherlands) consumption. Antibiotic consumption in the EU/EEA did not change significantly over time. Antibiotic consumption showed a significant seasonal variation, which decreased over time. The number of DDD per package significantly increased over time. The proportional consumption of sulphonamides and trimethoprim (J01E) relative to other groups significantly decreased over time, while the proportional consumption of other antibacterials (J01X) relative to other groups significantly increased over time.

Conclusions
Overall, antibiotic consumption in the community in the EU/EEA did not change during 1997–2017, while seasonal variation consistently decreased over time. The number of DDD per package increased during 1997–2017.
Burn Center Organization and Cellular Therapy Integration: Managing Risks and Costs
Authors: Chemali Michèle , Laurent Alexis , Scaletta Corinne , Waselle Laurent , Simon Jeanne-Pascale , Michetti Murielle , Brunet Jean-François , Flahaut Marjorie , Hirt-Burri Nathalie , Raffoul Wassim , Applegate Lee Ann , de Buys Roessingh Anthony S , Abdel-Sayed Philippe 
Published: May 2021

Abstract
The complex management of severe burn victims requires an integrative collaboration of multidisciplinary specialists in order to ensure quality and excellence in healthcare. This multidisciplinary care has quickly led to the integration of cell therapies in clinical care of burn patients. Specific advances in cellular therapy together with medical care have allowed for rapid treatment, shorter residence in hospitals and intensive care units, shorter durations of mechanical ventilation, lower complications and surgery interventions, and decreasing mortality rates. However, naturally fluctuating patient admission rates increase pressure toward optimized resource utilization. Besides, European translational developments of cellular therapies currently face potentially jeopardizing challenges on the policy front. The aim of the present work is to provide key considerations in burn care with focus on architectural and organizational aspects of burn centers, management of cellular therapy products, and guidelines in evolving restrictive regulations relative to standardized cell therapies. Thus, based on our experience, we present herein integrated management of risks and costs for preserving and optimizing clinical care and cellular therapies for patients in dire need.
The bursty origin of the Milky Way thick disc
Authors: Yu Sijie , Bullock James S , Klein Courtney , Stern Jonathan , Wetzel Andrew , Ma Xiangcheng , Moreno Jorge , Hafen Zachary , Gurvich Alexander B , Hopkins Philip F , Kereš Dušan , Faucher-Giguère Claude-André , Feldmann Robert , Quataert Eliot 
Published: May 2021

ABSTRACT
We investigate thin and thick stellar disc formation in Milky Way-mass galaxies using 12 FIRE-2 cosmological zoom-in simulations. All simulated galaxies experience an early period of bursty star formation that transitions to a late-time steady phase of near-constant star formation. Stars formed during the late-time steady phase have more circular orbits and thin-disc-like morphology at z = 0, while stars born during the bursty phase have more radial orbits and thick-disc structure. The median age of thick-disc stars at z = 0 correlates strongly with this transition time. We also find that galaxies with an earlier transition from bursty to steady star formation have a higher thin-disc fractions at z = 0. Three of our systems have minor mergers with Large Magellanic Cloud-size satellites during the thin-disc phase. These mergers trigger short starbursts but do not destroy the thin disc nor alter broad trends between the star formation transition time and thin/thick-disc properties. If our simulations are representative of the Universe, then stellar archaeological studies of the Milky Way (or M31) provide a window into past star formation modes in the Galaxy. Current age estimates of the Galactic thick disc would suggest that the Milky Way transitioned from bursty to steady phase ∼6.5 Gyr ago; prior to that time the Milky Way likely lacked a recognizable thin disc.
The GALAH survey: A census of lithium-rich giant stars
Authors: Martell Sarah L , Simpson Jeffrey D , Balasubramaniam Adithya G , Buder Sven , Sharma Sanjib , Hon Marc , Stello Dennis , Ting Yuan-Sen , Asplund Martin , Bland-Hawthorn Joss , De Silva Gayandhi M , Freeman Ken C , Hayden Michael , Kos Janez , Lewis Geraint F , Lind Karin , Zucker Daniel B , Zwitter Tomaž , Campbell Simon W , Čotar Klemen , Horner Jonathan , Montet Benjamin , Wittenmyer Rob 
Published: May 2021

Abstract
We investigate the properties of 1262 red giant stars with high photospheric abundances of lithium observed by the GALAH and K2-HERMES surveys, and discuss them in the context of proposed mechanisms for lithium enrichment and re-depletion in giant stars. We confirm that Li-rich giants are rare, making up only 1.2 per cent of our giant star sample. We use stellar parameters from the third public data release from the GALAH survey and a Bayesian isochrone analysis to divide the sample into first-ascent red giant branch and red clump stars, and confirm these classifications using asteroseismic data from K2. We find that red clump stars are 2.5 times as likely to be lithium-rich as red giant branch stars, in agreement with other recent work. The probability for a star to be lithium-rich is affected by a number of factors, though the causality in those correlations is not entirely clear. We show for the first time that primary and secondary red clump stars have distinctly different lithium enrichment patterns. The data set discussed here is large and heterogeneous in terms of evolutionary phase, metallicity, rotation rate and mass. We expect that if the various mechanisms that have been proposed for lithium enrichment in evolved stars are in fact active, they should all contribute to this sample of lithium-rich giants at some level.